Form D · Biotechnology

ELIXIRGEN THERAPEUTICS, INC.

Baltimore, MD · CIK 0001744333

Offering snapshot reported Nov 13, 2025 · SEC filing

Reported sold
$4M
Offering amount: $4M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 30, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 13, 2025Initial$4,000,000No comparison1SEC filing
Apr 9, 2025Initial$3,600,000No comparison2SEC filing
Feb 12, 2025Initial$600,000No comparison2SEC filing
Dec 1, 2023Initial$6,999,988No comparison1SEC filing
Sep 29, 2022Initial$5,000,000No comparison1SEC filing
Feb 18, 2021Initial$4,199,985No comparison2SEC filing
Aug 17, 2020Amendment$5,706,889$699,989vs Dec 2, 20193SEC filing
Dec 2, 2019Initial$5,006,900No comparison3SEC filing
Jun 25, 2018Initial$3,999,998No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-563910

Source: Form D, filed Nov 13, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Shauna Callahan Director
Jeffrey Cleland Director
Maiko Katadae Director
Akihiro Ko Director, Executive
Minoru Ko Director
Hiroaki Kobayashi Director
Naonori Kurokawa Director
Thomas White Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
855 N. Wolfe St. Suite 624
Baltimore, MD, 21205